The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
Go back to The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%| Regeneron (NASDAQ: REGN) | Delayed: 664.52 -3.43 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $667.95 | 52 Week High | $592.36 | |||
| Open | $670.06 | 52 Week Low | $325.35 | |||
| Day High | $676.66 | P/E | 174.41 | |||
| Day Low | $658.50 | EPS | $3.81 | |||
| Volume | 581,778 | |||||
